Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207074 | 0.91 | TACR1 (0.54) | TACR1NPC1MMP2MMP3KMT2A | |
| SCHEMBL207075 | 0.91 | TACR1 (0.54) | TACR1NPC1MMP2MMP3KMT2A | |
| Hydrochloric Acid SCHEMBL20996763 | 0.88 | FOLH1 (0.57) | TACR1PPARAFOLH1 | |
| SCHEMBL207546 | 0.84 | TACR1 (0.47) | TACR1NPC1MMP2MMP3KMT2A | |
| SCHEMBL207545 | 0.84 | TACR1 (0.47) | TACR1NPC1MMP2MMP3KMT2A | |
| SCHEMBL30872672 | 0.84 | FPR2 (0.62) | NPC1PPARAMMP2KMT2AATM | |
| SCHEMBL29228692 | 0.84 | FPR2 (0.62) | NPC1PPARAMMP2KMT2AATM | |
| SCHEMBL6160524 | 0.82 | S1PR1 (0.49) | TACR1PPARAATMHTTALDH1A1 | |
| SCHEMBL6160520 | 0.82 | S1PR1 (0.49) | TACR1PPARAATMHTTALDH1A1 | |
| SCHEMBL2715155 | 0.81 | BCHE (0.56) | KMT2AMEN1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088923-B2 | Cyclic-fused beta-lactones and their synthesis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090062547-A1 | CYCLIC-FUSED BETA-LACTONES AND THEIR SYNTHESIS | THE TEXAS A&M UNIVERSITY SYSTEM | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062547-A1 | CYCLIC-FUSED BETA-LACTONES AND THEIR SYNTHESIS | COASY, FASN, OTUB1 | TACR1 4422/4885NPC1 3149/4885PPARA 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.